347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial
oleh: Lucy Gilbert, Jameel Muzaffar, David McDermott, Vamsidhar Velcheti, Anna Spreafico, Valentina Boni, Christopher Hoimes, Ira Winer, Seth Rosen, Quincy Chu, Olivier Dumas, Aman Chauhan, Arvind Chaudhry, Piotr Tomczak, Debora Bruno, Elizabeth Dorn, Jessicca Rege
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2020-11-01 |
Deskripsi
No description available for this item.